Alixorexton (ALKS 2680)
Narcolepsy Type 1
Key Facts
About Alkermes
Alkermes is a neuroscience-focused biopharmaceutical company dedicated to making a meaningful difference for patients with complex and stigmatized conditions. The company's strategy integrates patient-inspired science, advanced development capabilities, and a commercial portfolio, including the recently acquired once-nightly sodium oxybate for narcolepsy. With a strong leadership team and a values-driven culture recognized as an employer of choice, Alkermes is advancing a pipeline of novel candidates, most notably the orexin 2 receptor agonist alixorexton, poised to enter Phase 3 trials for sleep disorders in 2026.
View full company profileAbout Alkermes
Alkermes is a neuroscience-focused biopharmaceutical company dedicated to making a meaningful difference for patients with complex and stigmatized conditions. The company's strategy integrates patient-inspired science, advanced development capabilities, and a commercial portfolio, including the recently acquired once-nightly sodium oxybate for narcolepsy. With a strong leadership team and a values-driven culture recognized as an employer of choice, Alkermes is advancing a pipeline of novel candidates, most notably the orexin 2 receptor agonist alixorexton, poised to enter Phase 3 trials for sleep disorders in 2026.
View full company profileAbout Alkermes
Alkermes is a neuroscience-focused biopharmaceutical company dedicated to making a meaningful difference for patients with complex and stigmatized conditions. The company's strategy integrates patient-inspired science, advanced development capabilities, and a commercial portfolio, including the recently acquired once-nightly sodium oxybate for narcolepsy. With a strong leadership team and a values-driven culture recognized as an employer of choice, Alkermes is advancing a pipeline of novel candidates, most notably the orexin 2 receptor agonist alixorexton, poised to enter Phase 3 trials for sleep disorders in 2026.
View full company profile